To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification of Major Interest in Mediclinic International plc shares

Release Date: 07/11/2018 15:30
Code(s): MEI     PDF:  
Wrap Text
Notification of Major Interest in Mediclinic International plc shares

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

7 November 2018

Notification of Major Interest in Mediclinic International plc shares

 1a. Identity of the issuer or the underlying issuer
 of existing shares to which voting rights are
 attached:                                                                 MEDICLINIC INTERNATIONAL PLC

 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
 Non-UK issuer

 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

 An acquisition or disposal of voting rights                                                            X

 An acquisition or disposal of financial instruments

 An event changing the breakdown of voting rights

 Other (please specify):

 3. Details of person subject to the notification obligation
 Name                                                         PUBLIC INVESTMENT CORPORATION SOC LIMITED
 City and country of registered office (if applicable)        PRETORIA, SOUTH AFRICA

 4. Full name of shareholder(s) (if different from 3.)

 Name

 City and country of registered office (if applicable)

 5. Date on which the threshold was crossed or
 reached:                                                     06/11/2018

 6. Date on which issuer notified (DD/MM/YYYY):               07/11/2018

 7. Total positions of person(s) subject to the notification obligation
                            % of voting rights      % of voting rights                              Total number of
                           attached to shares      through financial in-       Total of both in %   voting rights of
                              (total of 8. A)           struments                 (8.A + 8.B)       issuer
                                                    (total of 8.B 1 + 8.B 2)

Resulting situation
on the date on which
threshold was
crossed or reached             8.149%                                                    8.149%          737 243 810
Position of previous
notification (if
applicable)                    7.989%                                                    7.989%

 8. Notified details of the resulting situation on the date on which the threshold was crossed or
 reached

 A: Voting rights attached to shares
                           Number of voting rights                              % of voting rights
                                                         Indirect                                              Indirect
 Class/type of                  Direct               (Art 10 of Directive              Direct              (Art 10 of Directive
 shares                       (Art 9 of Directive        2004/109/EC)                (Art 9 of Directive       2004/109/EC)
 ISIN code (if possible)   2004/109/EC) (DTR5.1)           (DTR5.2.1)             2004/109/EC) (DTR5.1)          (DTR5.2.1)

                              60 077 807                                                8.149%




 SUBTOTAL 8. A                                60 077 807                                          8.149%



 B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
                                                                              Number of voting rights
                                                                              that may be acquired if
 Type of financial         Expiration        Exercise/                        the instrument is
 instrument                date              Conversion Period                exercised/converted.         % of voting rights




                                             SUBTOTAL 8. B 1                             NIL                        NIL


 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
 2004/109/EC (DTR5.3.1.1 (b))
                                             Exercise/            Physical or
 Type of financial     Expiration            Conversion           cash                  Number of
 instrument            date                  Period               settlement            voting rights      % of voting rights




                                                                                                                           
                                                                SUBTOTAL
                                                                8.B.2                      NIL                     NIL




9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)
                                                                   % of voting rights
                                 % of voting rights if it        through financial in-             Total of both if it
                                  equals or is higher            struments if it equals           equals or is higher
                                  than the notifiable            or is higher than the            than the notifiable
           Name                        threshold                  notifiable threshold                threshold
PUBLIC INVESTMENT
CORPORATION SOC
LIMITED                                   8.149%                                                          8.149%




10. In case of proxy voting, please identify:
Name of the proxy holder                                       N/A

The number and % of voting rights held                         N/A

The date until which the voting rights will be held            N/A



11. Additional information




                                                                                                                         
 Name: DEVILLIERS MAKONKO
 E-Mail: Devilliers.Makonko @pic.gov.za
 TEL: +27 12 742 3578



 Place of completion         PRETORIA, SOUTH AFRICA
 Date of completion          07 November 2018


Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on
the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd




                                                                                                              

Date: 07/11/2018 03:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story